UniProtKB/Swiss-Prot Q9NSK7: Variant p.Lys131Thr

Protein C19orf12
Gene: C19orf12
Feedback?

Variant information Variant position:

131 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

LB/B The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Lysine (K) to Threonine (T) at position 131 (K131T, p.Lys131Thr). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Change from large size and basic (K) to medium size and polar (T) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

-1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Other resources:

Links to websites of interest for the variant.

Variant rs79915936 [ dbSNP | Ensembl ]

Sequence information Variant position:

131 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

141 The length of the canonical sequence.
Location on the sequence:

VMGSEALQQQLLAMLVNYVT K ELRAEIQYDD The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         VMGSEALQQQLLAMLVNYVTKELRAEIQYDD

Mouse                         VMSNQAMQQRLLAMLTTYVTKELQAEIRYED

Bovine                        VMGSEALQKQLLAMLANYVTKELRAEVQYDD

Xenopus tropicalis            VMGNDSLKQKVVAALINYMTKELQAEIQYGD

Zebrafish                     VMGNASLQQQVTAALLSYIHKELQAEVHYID

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	1 – 141	Protein C19orf12
Alternative sequence	108 – 141	Missing. In isoform 3.

Literature citations
Absence of an orphan mitochondrial protein, c19orf12, causes a distinct clinical subtype of neurodegeneration with brain iron accumulation.
Hartig M.B.; Iuso A.; Haack T.; Kmiec T.; Jurkiewicz E.; Heim K.; Roeber S.; Tarabin V.; Dusi S.; Krajewska-Walasek M.; Jozwiak S.; Hempel M.; Winkelmann J.; Elstner M.; Oexle K.; Klopstock T.; Mueller-Felber W.; Gasser T.; Trenkwalder C.; Tiranti V.; Kretzschmar H.; Schmitz G.; Strom T.M.; Meitinger T.; Prokisch H.;
Am. J. Hum. Genet. 89:543-550(2011)
Cited for: VARIANTS NBIA4 ARG-42; GLU-54 AND ARG-58; VARIANT NBIA4 MET-11 (ISOFORM 4); VARIANTS GLU-131 AND THR-131; SUBCELLULAR LOCATION; INDUCTION; New NBIA subtype: genetic, clinical, pathologic, and radiographic features of MPAN.
Hogarth P.; Gregory A.; Kruer M.C.; Sanford L.; Wagoner W.; Natowicz M.R.; Egel R.T.; Subramony S.H.; Goldman J.G.; Berry-Kravis E.; Foulds N.C.; Hammans S.R.; Desguerre I.; Rodriguez D.; Wilson C.; Diedrich A.; Green S.; Tran H.; Reese L.; Woltjer R.L.; Hayflick S.J.;
Neurology 80:268-275(2013)
Cited for: VARIANTS NBIA4 PHE-28; PRO-37; ARG-42; LEU-49; GLU-54; VAL-54; ARG-58; LEU-72; SER-87 AND PRO-123; VARIANTS GLU-131; THR-131 AND ARG-138;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.